Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

47PInvestigating various thresholds as immunohistochemistry cut-offs for observer agreement

(2015) A. Ali et al.   ANNALS OF ONCOLOGY

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

(2015) M. V. Dieci et al.   ANNALS OF ONCOLOGY

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc

(2015) William M Sikov et al.   CANCER RESEARCH

Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)

(2015) Leisha A. Emens et al.   CANCER RESEARCH

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

(2015) Andrew Tutt et al.   CANCER RESEARCH

Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer

(2015) Rita Nanda et al.   CANCER RESEARCH

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer

(2015) M. Callari et al.   CLINICAL CANCER RESEARCH

Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models

(2015) M. Sameni et al.   CLINICAL CANCER RESEARCH

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

(2015) S. Loi et al.   CLINICAL CANCER RESEARCH

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

(2015) Melinda L. Telli et al.   JOURNAL OF CLINICAL ONCOLOGY

Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer

(2015) Fergus J. Couch et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

(2015) Steven J. Isakoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

(2015) Peter Savas et al.   Nature Reviews Clinical Oncology

Precision Medicine — Personalized, Problematic, and Promising

(2015) J. Larry Jameson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

(2015) M. C. U. Cheang et al.   ONCOLOGIST

Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers

(2015) J. Watkins et al.   Cancer Discovery

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial

(2014) G. Viale et al.   ANNALS OF ONCOLOGY

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

(2014) M. V. Dieci et al.   ANNALS OF ONCOLOGY

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

(2014) F. Cardoso et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

(2014) Ann E. McCullough et al.   BREAST CANCER RESEARCH AND TREATMENT

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

(2014) T. Byrski et al.   BREAST CANCER RESEARCH AND TREATMENT

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

(2014) A Prat et al.   BRITISH JOURNAL OF CANCER

Abstract S3-6: Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease

(2014) JM Balko et al.   CANCER RESEARCH

Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin

(2014) Katherine A. Hoadley et al.   CELL

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

(2014) S. D. Brown et al.   GENOME RESEARCH

Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2014) Ann H. Partridge et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Downfall of Iniparib: A PARP Inhibitor That Doesn't Inhibit PARP After All

(2014) G. Sinha   JNCI-Journal of the National Cancer Institute

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Clonal evolution in breast cancer revealed by single nucleus genome sequencing

(2014) Yong Wang et al.   NATURE

Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario

(2014) M. Bonotto et al.   ONCOLOGIST

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

(2014) H. Wimberly et al.   Cancer Immunology Research

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer

(2013) J. M. Balko et al.   CANCER RESEARCH

Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity

(2013) T. H. Kang et al.   CANCER RESEARCH

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

(2013) H. Masuda et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer

(2013) A. Gucalp et al.   CLINICAL CANCER RESEARCH

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

(2013) Jeffrey R. Infante et al.   EUROPEAN JOURNAL OF CANCER

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

(2013) Neil E. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

CD4+ follicular helper T cell infiltration predicts breast cancer survival

(2013) Chunyan Gu-Trantien et al.   JOURNAL OF CLINICAL INVESTIGATION

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

(2013) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

(2013) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

(2013) Brian D Lehmann et al.   JOURNAL OF PATHOLOGY

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Emerging landscape of oncogenic signatures across human cancers

(2013) Giovanni Ciriello et al.   NATURE GENETICS

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

(2013) A. Prat et al.   ONCOLOGIST

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

(2013) Yasmin Issa-Nummer et al.   PLoS One

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis

(2013) Srikanth Nagalla et al.   GENOME BIOLOGY

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials

(2012) J. Huober et al.   ANNALS OF ONCOLOGY

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

(2012) L. Malorni et al.   BREAST CANCER RESEARCH AND TREATMENT

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

(2012) V Abkevich et al.   BRITISH JOURNAL OF CANCER

Breast cancer, side population cells and ABCG2 expression

(2012) K.M. Britton et al.   CANCER LETTERS

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

(2012) T. Popova et al.   CANCER RESEARCH

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

(2012) James S. Duncan et al.   CELL

Recent agents targeting HIF-1α for cancer therapy

(2012) Yaozhong Hu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry

(2012) Takayuki Iwamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

(2012) Lisa A. Carey et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis

(2012) Michail Ignatiadis et al.   JOURNAL OF CLINICAL ONCOLOGY

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

(2012) Dai Horiuchi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

(2012) D. W. Craig et al.   MOLECULAR CANCER THERAPEUTICS

Sequence analysis of mutations and translocations across breast cancer subtypes

(2012) Shantanu Banerji et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

(2012) Justin M Balko et al.   NATURE MEDICINE

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways

(2012) A Bianchi-Smiraglia et al.   ONCOGENE

Raising the Bar: The Curative Potential of Human Cancer Immunotherapy

(2012) S. A. Rosenberg   Science Translational Medicine

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

(2012) Yasir H. Ibrahim et al.   Cancer Discovery

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents

(2012) Nicolai J. Birkbak et al.   Cancer Discovery

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors

(2011) Lauren L.C. Marotta et al.   JOURNAL OF CLINICAL INVESTIGATION

Multifactorial Approach to Predicting Resistance to Anthracyclines

(2011) Christine Desmedt et al.   JOURNAL OF CLINICAL ONCOLOGY

Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers

(2011) Daniel Wetterskog et al.   JOURNAL OF PATHOLOGY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Tumour evolution inferred by single-cell sequencing

(2011) Nicholas Navin et al.   NATURE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

A gene expression signature identifies two prognostic subgroups of basal breast cancer

(2010) Renaud Sabatier et al.   BREAST CANCER RESEARCH AND TREATMENT

Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor

(2010) H. Harrison et al.   CANCER RESEARCH

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers

(2010) Giampaolo Bianchini et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2010) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome

(2010) Johan Staaf et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Epithelial-Mesenchymal Transition (EMT) in Tumor-Initiating Cells and Its Clinical Implications in Breast Cancer

(2010) Chad J. Creighton et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Genome remodelling in a basal-like breast cancer metastasis and xenograft

(2010) Li Ding et al.   NATURE

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy

(2009) V. Guarneri et al.   ANNALS OF ONCOLOGY

Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis

(2009) E. H. Huang et al.   CANCER RESEARCH

Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature

(2009) Emmanuelle Charafe-Jauffret et al.   CANCER RESEARCH

A Novel Lung Metastasis Signature Links Wnt Signaling with Cancer Cell Self-Renewal and Epithelial-Mesenchymal Transition in Basal-like Breast Cancer

(2009) Theresa A. DiMeo et al.   CANCER RESEARCH

Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer

(2009) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

Aldehyde Dehydrogenase 1-Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer

(2009) E. Charafe-Jauffret et al.   CLINICAL CANCER RESEARCH

Integrins in mammary-stem-cell biology and breast-cancer progression - a role in cancer stem cells?

(2009) S. M. Pontier et al.   JOURNAL OF CELL SCIENCE

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle

(2009) Maximina H. Yun et al.   NATURE

Histological and molecular types of breast cancer: is there a unifying taxonomy?

(2009) Britta Weigelt et al.   Nature Reviews Clinical Oncology

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

(2009) C. J. Creighton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

(2008) O. Gluz et al.   ANNALS OF ONCOLOGY

Linking the Cellular Functions of BRCA Genes to Cancer Pathogenesis and Treatment

(2008) Ashok R. Venkitaraman   Annual Review of Pathology-Mechanisms of Disease

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

(2008) Robin L. Jones et al.   BREAST CANCER RESEARCH AND TREATMENT

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

(2008) M. Schmidt et al.   CANCER RESEARCH

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

(2008) C. Desmedt et al.   CLINICAL CANCER RESEARCH

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

(2008) Nicholas C Turner et al.   EMBO JOURNAL

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer

(2008) C A Crane et al.   ONCOGENE